The discovery of synthetic lethality between BRCA mutations and PARP inhibitors ranks has led to major advances in the treatment of BRCA-mutated cancers. Mutations in BRCA1 and BRCA2 can leave cells with a deficiency in homologous repair (HR). And that deficiency can make them vulnerable to PARP inhibitors, which block alternate DNA repair pathways, as well as platinum-based treatment, which induces DNA mutations that BRCA-deficient cells are unable to cope with.
PERTH, Australia – The FDA granted Oncores Medical Pty. Ltd. breakthrough device designation for its quantitative micro-elastography (QME) imaging system. The hand-held imaging tool helps surgeons differentiate between cancerous and healthy tissue in real time at the point of surgery, and it could substantially improve outcomes in breast-conserving surgery (BCS) and reduce repeat operations for women with breast cancer.
PERTH, Australia – Imagion Biosystems Ltd. has entered a collaborative research program with therapeutic antibody development company Patrys Ltd. to combine their technologies to target brain tumor imaging and diagnosis.
Molli Surgical Inc. has won the FDA’s nod for its wire-free localization technology for breast cancer surgery. The company said the Molli system helps radiologists tag cancerous lesions quickly and precisely, facilitating surgical excision and eliminating a source of anxiety associated with breast tumor removal.
Twenty years after the first, exclusively white human genomes were fully sequenced, science finds itself in the same position as the rest of society: with the uncomfortable realization that old inequalities are often morphing, rather than disappearing. Vocal racists – scientists of the stripe of a James Watson – are by no means a thing of the past. But they are only the tip of the iceberg.
Castle Biosciences Inc. deepened the moat around its position in melanoma diagnostics with the acquisition of Myriad Mypath LLC from Myriad Genetics Inc. The acquisition gives Castle (NASDAQ:CSTL) the Myriad Mypath Laboratory in Salt Lake City where the Mypath Melanoma 23-gene expression profile (GEP) test is owned and offered. Mypath Melanoma joins Castle's Decisiondx Diffdx-Melanoma, enabling Castle to provide comprehensive molecular testing for difficult-to-diagnose melanocytic lesions.
TORONTO – Breath analytics technology developed by Picomole Inc. and University of New Brunswick (UNB) researchers promises to identify lung cancer long before it reaches the most advanced stages of the disease. Machine learning sits at the heart of the system, evaluating raw spectral data from a patient’s breath for early diagnosis of lung cancer, Steve Graham, CEO of Moncton, New Brunswick-based Picomole, told BioWorld.
A study led by Chinese radiologists at Peking University in Beijing has shown that positron emission tomography imaging of intercellular adhesion molecule-1 (ICAM-1) expression is a predictor for the abscopal effect, whereby nonirradiated cancers respond to radiotherapy.
The FDA has approved Roche AG’s Ventana MMR Rxdx panel for patients with advanced or recurrent endometrial cancer. The companion diagnostic is the first to identify patients who are eligible for treatment with Glaxosmithkline plc’s (GSK’s) Jemperli (dostarlimab-gxly) monotherapy. The PD-1 antibody immunotherapy received FDA approval on Thursday.
Koelis SAS reported the first successful procedures for its platform in 3D fusion imaging-guided focal ablation of prostate cancer at the Clinique Nantes Atlantis in Saint-Herblain, France. These first procedures take place against the background of a multicenter prospective clinical trial starting on the Koelis platform. This includes eight European urology centers, of which six are in France, with data being stored in a dedicated registry.